BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched today with $177 million in Series A financing. The financing was co-led by Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors. Antares is a spin-out of Scor